高剂量质子束治疗对比常规分割放疗用于新诊断胶质母细胞瘤的倾向性评分匹配分析
本研究利用倾向性评分匹配比较2010至2020年间新诊断胶质母细胞瘤患者接受高剂量质子束治疗96.6 Gy(RBE)或常规放疗60 Gy的生存结局与毒性。匹配后每组26例,质子束治疗组中位总生存28.3个月,常规放疗组21.2个月。两组急性放射相关毒性相当,但质子束治疗组放射性坏死作为晚期毒性显著更常见。
要点
- 高剂量质子束治疗96.6 Gy(RBE)较常规放疗60 Gy显示显著生存获益。
- 匹配后每组26例,质子束治疗组中位总生存28.3个月 vs 常规放疗组21.2个月。
- 两组急性毒性相当,但质子束治疗组晚期放射性坏死显著更常见。
核心结论
- 高剂量质子束治疗较常规放疗为新诊断胶质母细胞瘤患者提供显著生存获益。
- 放射性坏死仍是高剂量质子束治疗的问题,作者认为建立以贝伐珠单抗为中心的有效治疗策略至关重要。
研究设计与样本
- 本研究为倾向性评分匹配分析,纳入2010至2020年间新诊断胶质母细胞瘤患者,接受高剂量质子束治疗96.6 Gy(RBE)或常规放疗60 Gy。
- 基于年龄、性别、肿瘤位置、切除范围、化疗、免疫治疗和放疗前卡氏功能状态评分进行倾向性评分生成及1:1匹配。
- 从总共235例患者中,每组各匹配26例。
主要发现
- 质子束治疗组中位总生存为28.3个月,常规放疗组为21.2个月。
- 质子束治疗组与常规放疗组急性放射相关毒性相当。
- 质子束治疗组放射性坏死作为晚期放射相关毒性显著更频繁观察到。
关键数值与推荐
- 高剂量质子束治疗剂量为96.6 Gy(RBE),常规放疗剂量为60 Gy。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: High-dose proton beam therapy (PBT) uses excellent dose concentricity based on the unique characteristic termed the Bragg peak. PBT is a highly feasible treatment option that improves survival in select patients with newly diagnosed glioblastoma (GBM). However, selection bias remains an issue in prior studies that evaluated the efficacy of PBT. The aim of the present study was to compare the survival outcomes and toxicities of high-dose PBT and conventional radiation therapy (CRT) using propensity score-matched treatment cohorts. METHODS: The analysis included patients with newly diagnosed GBM treated with high-dose PBT of 96.6 Gy (RBE) or CRT of 60 Gy from 2010 to 2020. Propensity score generation and 1:1 matching of patients were performed based on the following covariates: age, sex, tumor location, extent of resection, chemotherapy, immunotherapy, and pre-radiation Karnofsky performance scale score. RESULTS: From a total of 235 patients, 26 were selected in each group by propensity score matching. The median overall survival (OS) of the PBT group was 28.3 months, while the median OS of the CRT group was 21.2 months. Although acute radiation-related toxicities were equivalent between the PBT and CRT groups, radiation necrosis as a late radiation-related toxicity was observed significantly more frequently in the PBT group. CONCLUSIONS: High-dose PBT provided significant survival benefits for patients with newly diagnosed GBM compared to CRT as shown by propensity score matching analysis. Radiation necrosis remains an issue in high-dose PBT; thus, the establishment of an effective treatment strategy centered on bevacizumab would be essential.
引用
- Matsuda M, Mizumoto M, Kohzuki H, et al. High-dose proton beam therapy versus conventional fractionated radiation therapy for newly diagnosed glioblastoma: a propensity score matching analysis. Radiat Oncol. 2023. PMID: 36823671. doi:10.1186/s13014-023-02236-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。